Results 141 to 150 of about 18,017 (247)

Calibration-free electrochemical sensor to monitor factor-Xa inhibitors at the point-of-care anticoagulation therapy

Calibration-free electrochemical sensor to monitor factor-Xa inhibitors at the point-of-care anticoagulation ...
Angel Torriero (13058478), Ashwin KV Mruthunjaya (14394558), Ronald C Chatelier (15855812)   +2 more
core  

Effect of the oral, direct factor Xa-inhibitors on global coagulation assays and thrombocyte activation

, 2017
Obwohl der Einsatz der Faktor Xa-Inhibitoren keines routinemäßigen Monitorings bedarf, gibt es Situationen im klinischen Alltag, in denen eine Einschätzung ihrer Wirkung notwendig ist.
Dobler, Franziska Ursula
core  

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures

Transfusion, Volume 66, Issue 6, Page 1203-1209, June 2026.
Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Mohammad Shamiea, Alex Osnis, Awan Kashoua, Orli Avnery, Gilad Itchaki, Shuli Isman, Tali Tohami, Osnat Jarchowsky‐Dolberg, Martin Ellis   +8 more
wiley   +1 more source

Residue‑resolved dynamically averaged interaction analysis of direct factor Xa inhibitors by MD‑FMO combination calculations. [PDF]

J Comput Aided Mol Des
Yoshine R, Hirano Y, Doi H, Kitahara S, Akisawa K, Okuwaki K, Yamamoto E, Yasuoka K, Mochizuki Y.   +8 more
europepmc   +1 more source

The 5 most frequently asked questions about factor Xa inhibitors. [PDF]

Hematology Am Soc Hematol Educ Program, 2022
Wang TF, Carrier M.
europepmc   +1 more source

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. [PDF]

Cochrane Database Syst Rev, 2023
Li M, Li J, Wang X, Hui X, Wang Q, Xie S, Yan P, Tian J, Li J, Xie P, Yang K, Yao L.   +11 more
europepmc   +1 more source

The impact of body composition variability on coagulation monitoring in patients on direct oral factor Xa inhibitors for treatment of venous thromboembolism. [PDF]

Front Cardiovasc Med
Kurzmann-Guetl K, Leitner DR, Gary T, Avian A, Beck A, Rabensteiner J, Prueller F, Raggam RB, Brodmann M, Toplak H.   +9 more
europepmc   +1 more source

Incomplete harms reporting in systematic reviews of direct oral factor Xa inhibitors. [PDF]

Blood Adv
Rea J, Lee C, Kee M, Rucker B, Flores H, Walters C, Haney T, Tomlin A, Khan A, Vassar M.   +9 more
europepmc   +1 more source

Use of andexanet alfa: A British Society for Haematology position statement

British Journal of Haematology, Volume 208, Issue 6, Page 1939-1941, June 2026.
Richard J. Buka, Deepa J. Arachchillage, Catherine N. Bagot, Gary Benson, Charlotte A. Bradbury, Nicola Curry, Beverley J. Hunt, David J. Sutton, Mari R. Thomas, John Paul Westwood, Karen Breen   +10 more
wiley   +1 more source

Position statement of the Polish Society of Gastroenterology on the use of andexanet alfa in patients with gastrointestinal bleeding taking factor Xa inhibitors. [PDF]

Prz Gastroenterol
Adrych K, Daniluk J, Nowakowska-Duława E, Białek A, Rydzewska GM.   +4 more
europepmc   +1 more source